LTI-03, an experimental treatment for idiopathic pulmonary fibrosis (IPF) that’s currently in clinical testing, was shown to reduce inflammation and scarring in experiments done on lung tissue collected from IPF patients, according to a study. The study showed that LTI-03’s effects on inflammation and scarring were similar to those…
From the day I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, I set out to learn everything I could about the disease. This included how to tell others about IPF, which is so named because its cause isn’t known. When a transplant isn’t a viable…
GRI-0621, an experimental oral therapy for idiopathic pulmonary fibrosis (IPF), may stabilize lung function, according to an interim analysis of an ongoing Phase 2a study. Forced vital capacity (FVC), a measure of how much air a person can forcibly exhale, didn’t worsen during the first six weeks of the…
I’m at it again; I’m job hunting, or seeking employment, if you will. But this time, the search carries more weight. It’s not just about finding work; it’s about reclaiming a part of myself that I thought I’d lost. Teaching has always been my passion, the steady flame that keeps…
There will be times when, despite everything you cover in planning for a trip, something happens that you didn’t anticipate. I can guarantee it. I shared with you my vacation details and preparations in my Aug. 26 column, all made to ensure the entire trip would be an opportunity…
Using a specialized lab technique, a collaborative U.S. research team identified cellular changes in the body that could be early drivers of lung scarring (fibrosis) in people with pulmonary fibrosis (PF). That’s according to the findings of a new study in which the researchers, from three universities, exposed lung…
Second in a series. Read part 1 about the foundation’s work of the past 25 years. During my interview with Scott Staszak, president and CEO of the Pulmonary Fibrosis Foundation (PFF), I was struck by his passion for the foundation’s work. I asked him to share his thoughts…
The inhalation therapy Tyvaso (treprostinil) significantly improved a measure of lung function for people with idiopathic pulmonary fibrosis (IPF) in a Phase 3 clinical trial. The top-line result means that the Phase 3 TETON 2 clinical trial (NCT05255991) has met its main goal. Tyvaso’s developer, United…
First in a series. Shortly after I learned I had idiopathic pulmonary fibrosis (IPF) in January 2017, I came to rely on the Pulmonary Fibrosis Foundation (PFF) as a reliable source of information. That relationship continues today, more than four years after my bilateral lung transplant in…
September is Pulmonary Fibrosis Awareness Month, and organizations around the world are gearing up to educate others and bring attention to pulmonary fibrosis (PF) — and also interstitial lung diseases (ILDs), which are disorders marked by scarring in the lungs. “We urgently need broader awareness because with it…
Get regular updates to your inbox.
